PPI’s and their risks, in perspective, from the ACG President.
The biggest admitted downside of PPI therapy at their introduction was cost. With the advent of over-the-counter and generic PPI’s, cost took a back seat and many more patients were managed on chronic, long-term PPI’s with no real attempt to stop or decrease that therapy. Over the past several years, a number of potential adverse effects of PPI therapy have been suggested by large, observational studies. The current President of the ACG discusses the known and theoretical risks of therapy and advises both caution and continued use when appropriate.